Liberman Alexander M. 4

What Happened

• Alexander M. Liberman, Chief Legal Officer of Medline (MDLN), was the recipient of multiple grants/awards reported on a Form 4 covering transactions dated December 16, 2025 (and one entry dated March 5, 2026). The filings show a series of acquisitions/awards across different instruments totaling 2,382,831 units/shares (a mix of Class B common stock, restricted stock units (RSUs), and several categories of Incentive Units/profit interests). Most awards list no cash price (N/A); one small grant of 11,903 shares was recorded on 2026-03-05 at $0.00 (no cash paid).

Key Details

• Transaction dates and prices:
  • Primary activity dated 2025-12-16 (multiple awards; price listed as N/A).
  • One entry on 2026-03-05: 11,903 shares acquired at $0.00.
• Total quantity reported across entries: 2,382,831 units/shares (aggregate of direct and derivative interests).
• Notable vesting and instrument details:
  • Several items are Incentive Units (profit interests) convertible into Common Units and ultimately exchangeable one-for-one into Class A shares per the Exchange Agreement; conversion mechanics and no expiration are described in the filing.
  • RSUs granted: 25% vest on June 15, 2026; remaining 75% vest in three equal annual installments beginning March 1, 2027.
  • Various Incentive Unit tranches have differing vesting schedules (examples in the filing: 20% vested / 80% vesting in four annual installments from Mar 29, 2026; five equal annual installments beginning Mar 28, 2026; 80% vested / 20% vesting Oct 21, 2026; 40% vested / remaining 60% vesting in three equal annual installments beginning Apr 1, 2026).
  • Class B common stock (where applicable) carries one vote per share but is described as having no economic value; Common Units are exchangeable for Class A shares under the Exchange Agreement.
• Holding structure notes:
  • Some securities are held indirectly through Medline Management Aggregator LLC.
  • Some securities are held in a trust of which the reporting person’s spouse is trustee.
• Filing timeliness:
  • The Form 4 was filed on March 6, 2026 for transactions dated December 16, 2025 (and one on March 5, 2026), which indicates a late filing relative to the usual two‑business‑day Form 4 deadline.

Context

• These transactions appear to be awards and reclassifications tied to pre‑IPO structuring and ongoing executive compensation (per footnotes describing reclassification prior to the IPO and exchange rights), not open‑market purchases or sales. Awards and incentive/profit‑interest units are typically subject to vesting and conversion mechanics; they do not necessarily reflect immediate cash investment or sales.
• For retail investors: vesting schedules and conversion rights determine when these interests can convert to economically valuable Class A shares; many of the reported interests remain subject to future vesting and conversion conditions.